Sectors & IndustriesHealthcareDrug Manufacturers - General

Best General Drug Manufacturer Stocks to Buy Now (2022)

Top general drug manufacturer stocks in 2022 ranked by overall Zen Score. See the best general drug manufacturer stocks to buy now, according to analyst forecasts for the drug manufacturers - general industry.

According to Zen Score, the 3 best general drug manufacturer stocks to buy right now are:

HORIZON THERAPEUTICS PUBLIC (NASDAQ:HZNP) is the top general drug manufacturer stock with a Zen Score of 72, which is 28 points higher than the general drug manufacturer industry average of 44. It passed 24 out of 33 due diligence checks and has strong fundamentals. HORIZON THERAPEUTICS PUBLIC has seen its stock lose -7.55% over the past year, underperforming other general drug manufacturer stocks by -14 percentage points.

HORIZON THERAPEUTICS PUBLIC has an average 1 year price target of $132.57, an upside of 50.6% from HORIZON THERAPEUTICS PUBLIC's current stock price of $88.03.

HORIZON THERAPEUTICS PUBLIC stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 7 analysts covering HORIZON THERAPEUTICS PUBLIC, 57.14% have issued a Strong Buy rating, 28.57% have issued a Buy, 14.29% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

GILEAD SCIENCES (NASDAQ:GILD) is the second best general drug manufacturer stock with a Zen Score of 65, which is 21 points higher than the general drug manufacturer industry average of 44. It passed 23 out of 38 due diligence checks and has strong fundamentals. GILEAD SCIENCES has seen its stock lose -4.57% over the past year, underperforming other general drug manufacturer stocks by -11 percentage points.

GILEAD SCIENCES has an average 1 year price target of $69.46, an upside of 7.93% from GILEAD SCIENCES's current stock price of $64.35.

GILEAD SCIENCES stock has a consensus Hold recommendation according to Wall Street analysts. Of the 11 analysts covering GILEAD SCIENCES, 18.18% have issued a Strong Buy rating, 18.18% have issued a Buy, 54.55% have issued a hold, while 0% have issued a Sell rating, and 9.09% have issued a Strong Sell.

JOHNSON & JOHNSON (NYSE:JNJ) is the third best general drug manufacturer stock with a Zen Score of 56, which is 12 points higher than the general drug manufacturer industry average of 44. It passed 21 out of 38 due diligence checks and has strong fundamentals. JOHNSON & JOHNSON has seen its stock return 6.36% over the past year.

JOHNSON & JOHNSON has an average 1 year price target of $187.17, an upside of 3.18% from JOHNSON & JOHNSON's current stock price of $181.40.

JOHNSON & JOHNSON stock has a consensus Buy recommendation according to Wall Street analysts. Of the 6 analysts covering JOHNSON & JOHNSON, 16.67% have issued a Strong Buy rating, 33.33% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 13 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

GSK (NYSE:GSK) has an annual dividend yield of 4.5%, which is 1 percentage points higher than the general drug manufacturer industry average of 3.07%. GSK's dividend payout is not stable, having dropped more than 10% ten times in the last 10 years. GSK's dividend has not shown consistent growth over the last 10 years.

GSK's dividend payout ratio of 86.4% indicates that its high dividend yield is sustainable for the long-term.

GILEAD SCIENCES (NASDAQ:GILD) has an annual dividend yield of 4.44%, which is 1 percentage points higher than the general drug manufacturer industry average of 3.07%. GILEAD SCIENCES's dividend payout is stable, having never dropped by more than 10% in the last 10 years. GILEAD SCIENCES's dividend has shown consistent growth over the last 10 years.

GILEAD SCIENCES's dividend payout ratio of 79.4% indicates that its high dividend yield is sustainable for the long-term.

NOVARTIS AG (NYSE:NVS) has an annual dividend yield of 3.65%, which is 1 percentage points higher than the general drug manufacturer industry average of 3.07%. NOVARTIS AG's dividend payout is not stable, having dropped more than 10% three times in the last 10 years. NOVARTIS AG's dividend has shown consistent growth over the last 10 years.

NOVARTIS AG's dividend payout ratio of 31.1% indicates that its dividend yield is sustainable for the long-term.

General drug manufacturer stocks were up 1.01% in the last day, and up 0.87% over the last week.

We couldn't find a catalyst for why general drug manufacturer stocks are up.

Based on WallStreetZen's Valuation Score, the 3 most undervalued general drug manufacturer stocks right now are:

GILEAD SCIENCES (NASDAQ:GILD) is the most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. GILEAD SCIENCES has a valuation score of 71, which is 36 points higher than the general drug manufacturer industry average of 35. It passed 5 out of 7 valuation due diligence checks.

GILEAD SCIENCES's stock has dropped -4.57% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -11 percentage points.

HORIZON THERAPEUTICS PUBLIC (NASDAQ:HZNP) is the second most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. HORIZON THERAPEUTICS PUBLIC has a valuation score of 57, which is 22 points higher than the general drug manufacturer industry average of 35. It passed 4 out of 7 valuation due diligence checks.

HORIZON THERAPEUTICS PUBLIC's stock has dropped -7.55% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -14 percentage points.

BIOGEN (NASDAQ:BIIB) is the third most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. BIOGEN has a valuation score of 57, which is 22 points higher than the general drug manufacturer industry average of 35. It passed 4 out of 7 valuation due diligence checks.

BIOGEN's stock has dropped -27.37% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -34 percentage points.